Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Ye Hua
Ye Hua
Positions:

 Head of Clinical Development & Regulatory Affairs

Company:

 Hutchison MediPharma Holdings Ltd.

Ye Hua, MD, MPH is Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison  MediPharm, a novel drug R&D company focusing on drug discovery and development for innovative therapies in oncology and autoimmune diseases. Managing the clinical and regulatory organization, Dr. Hua is responsible for advancing clinical development pipeline and registering new drugs in China and ex-China. Under his leadership, the clinical development programs have grown from 5 small molecules in 7 Phase 1 oncology clinical trials to 8 small molecules in over 30 Phase 1-3 clinical trials in oncology and immunology in China, Australia, and USA. Most recently, Dr. Hua led fruquintinib NDA submission in mCRC indication via MAH policy.

Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He worked as a cancer epidemiologist at Shanghai Cancer Institute between 1992 and 1996, and then went to McGill University in Montreal Canada to pursue a Master Degree in cancer epidemiology. 

Dr. Hua is a senior clinical research physician who has over seventeen years’ global clinical development and new drug registration experience in the pharmaceutical industry. He started his career in the pharmaceutical industry as a biostatistician at Pharmacia & Upjohn in 1999, and worked through the rank in biostatistics. His most significant achievement being the statistical team leader for the pivotal Phase 3 RA registration trial of Humira that won regulatory approval in the US and EU. 

Often contributed to clinical programs beyond his role in statistics, Dr. Hua was well recognized and greatly appreciated by cross-functional development teams. In 2004, one year after joining Novartis, Dr. Hua successfully switched career track back to clinical. Being a medical monitor, he led a number of global Phase II/III registration trials in osteoarthritis, osteoporosis, infectious diseases, oncology and hematology disease areas. As clinical project leader, Dr. Hua contributed to the regulatory approval and life-cycle management for Reclast/Aclasta, Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. His last job in the US was Senior Director, Global Clinical Development, Celgene Corporation where he led several global clinical teams for Revlimid and Pomalyst NDA/sNDA in multiple myeloma indication, and eventually obtained regulatory approval in the US and EU. In addition, he led clinical subteam executed registration trials for Revlimid and Pomalyst in China, and successfully obtained Revlimid regulatory approval in multiple myeloma indication.